---
company: InnovAge Holding Corp.
ticker: INNV
form: 8-K
filed: 2026-05-05
accession: 0001834376-26-000018
source: https://www.sec.gov/Archives/edgar/data/1834376/000183437626000018/
---

# InnovAge Holding (INNV) earnings release, May 5, 2026

InnovAge Holding Corp. (INNV) · Form 8-K, Item 2.02 · Filed 2026-05-05 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1834376/000183437626000018/)

INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE

FISCAL THIRD QUARTER ENDED MARCH 31, 2025

DENVER, CO., May 5, 2026

(GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal third quarter ended March 31, 2026.

We delivered a solid third quarter, reflecting continued improvement in operating execution and financial performance,” said Patrick Blair, Chief Executive Officer of InnovAge. “These results are being driven by stronger performance across our centers and the benefits of the investments we’ve made over the past several years to strengthen our platform. At the same time, we continue reinvesting in our clinical teams, technology, and quality capabilities to further improve participant outcomes and experience over the long term. Based on our performance year to date, we are raising our fiscal 2026 revenue and Adjusted EBITDA guidance.

Financial Results

Fiscal Third Quarter 2026 Financial Performance

• Total revenues of $251.9 million, increased approximately 15.5% compared to $218.1 million in the third quarter of fiscal year 2025

• Loss Before Income Taxes of $29.8 million decreased approximately 169.2%, compared to a Loss Before Income Taxes of $11.1 million in the third quarter of fiscal year 2025

• Loss Before Income Taxes as a percent of revenue was 11.8%, an increase of 6.7 percentage points, compared to Loss Before Income Tax as a percent of revenue of 5.1% in the third quarter of fiscal year 2025

• Center-level Contribution Margin

(1) of $61.0 million, increased 49.8% compared to $40.7 million in the third quarter of fiscal year 2025

• Center-level Contribution Margin

(1) as a percent of revenue was 24.2%, an increase of 5.5 percentage points compared to 18.7% in the third quarter of fiscal year 2025

• Net loss of $29.9 million, compared to net loss of $11.1 million in the third quarter of fiscal year 2025

• Net loss margin of 11.9%, an increase of 6.8 percentage points, compared to a net loss margin of 5.1% in the third quarter of fiscal year 2025

• Net loss attributable to InnovAge Holding Corp. of $29.5 million, or loss per share of $0.22, compared to net loss attributable to InnovAge Holding Corp. of $11.4 million, or a loss per share of $0.08 in the third quarter of fiscal year 2025

• Adjusted EBITDA

(1) of $30.5 million, an increase of $19.7 million, compared to Adjusted EBITDA of $10.8 million in the third quarter of fiscal year 2025

• Adjusted EBITDA

(1) margin of 12.1%, an increase of 7.2 percentage points, compared to 4.9% in the third quarter of fiscal year 2025

• Census of approximately 8,050 participants compared to 7,530 participants in the third quarter of fiscal year 2025

• Ended the third quarter of fiscal year 2026 with $95.5 million in cash and cash equivalents plus $43.1 million in short-term investments, and $69.4 million in debt on the balance sheet, representing debt under the Company’s senior secured term loan, revolving credit facility and finance lease obligations

(1)

Center-level Contribution Margin and Center-level Contribution Margin as a percentage of revenue, Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. For more details and for a definition and reconciliation of these non-GAAP measures to the most closely comparable GAAP measures for the periods indicated, see “Note Regarding Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Measures” below.

Full Fiscal Year 2026 Financial Guidance

Based on information as of today, May 5, 2026, InnovAge is raising total revenues and Adjusted EBITDA guidance for the full year fiscal 2026. Census and Total Member Months remain unchanged.

Expected results and estimates may be impacted by factors outside the Company’s control, and actual results may be materially different from this guidance. See “Forward-Looking Statements - Safe Harbor” included herein.

(1)

We define Total Member Months as the total number of participants as of period end multiplied by the number of months within a year in which each participant was enrolled in our program. Management believes this is a useful metric as it more precisely tracks the number of participants the Company serves throughout the year.

(2)

Adjusted EBITDA is a non-GAAP measure. See “Note Regarding Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Measures” for a definition of Adjusted EBITDA and a reconciliation to net income (loss), the most closely comparable GAAP measure. The Company is unable to provide guidance for net income (loss) or a reconciliation of the Company’s Adjusted EBITDA guidance because it cannot provide a meaningful or accurate calculation or estimation of certain reconciling items without unreasonable effort. The Company’s inability to do so is due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including variations in effective tax rate, expenses to be incurred for acquisition activities and other one-time or exceptional items.

Conference Call

The Company will host a conference call this afternoon at 5:00 PM Eastern Time. A live audio webcast of the call will be available on the Company’s website, https://investor.innovage.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for a limited time. To access the call by phone, please go to this link ( registration link), for dialing instructions and a unique access pin. We encourage participants to dial into the call fifteen minutes ahead of the scheduled start time.

About InnovAge... (truncated)nantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care our participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers and government payors — “win.” As of March 31, 2026, InnovAge served approximately 8,050 participants across 20 centers in six states. https://www.innovage.com.

Investor Contact:

Ryan Kubota rkubota@innovage.com

Media Contact: press@innovage.com

Forward-Looking Statements - Safe Harbor

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.

Forward-looking statements may be identified by the fact that they do not relate strictly to historical or current facts. Examples of forward-looking statements include, among others, statements we may make regarding quarterly or annual guidance; financial outlook, including future revenues and future earnings; mid-term and long-term financial goals; the viability of our growth strategy including our ability or expectations to increase the number of participants we serve, build and/or open de novo centers, or to identify and execute tuck-in acquisitions, joint ventures and other strategic partnerships; the expected impact of government policies including rate pressures resulting from Medicaid budget cuts, and the macroeconomic environment; our ability to control costs, mitigate the effects of elevated expenses or reduced healthcare budgets, expand our payer capabilities, execute clinical value and operational value initiatives and strengthen enterprise functions; and the effects of any of the foregoing on our future results of operations or financial conditions.

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control and may cause our actual results and financial condition to differ materially. Important factors that could cause our actual results and financial condition to differ materially include, among others, the following: (i) the viability of our growth strategy, including our ability to find suitable geographies for new centers and to attract new participant and retain existing participants in new and existing centers and our ability to obtain licenses to open such centers; (ii) our ability to identify, successfully complete and integrate acquisitions, joint ventures another strategic partnerships; (iii) the impact of state and federal efforts to reduce healthcare spending, including recent legislation reducing the budget that funds Medicaid (iv) the impact on our business from macroeconomic related challenges, including labor shortages and labor competition; (v) inspections, reviews, audits and investigations under the federal and state government programs, including our ability to sufficiently cure any deficiencies identified; (vi) legal proceedings, enforcement actions and litigation and disputes; (vii) the risk that the cost of providing services will exceed our compensation, which we assume under our PACE contracts; (viii) the dependence of our revenues upon a limited number of government payors, including the risk of sudden loss of any of our government contracts; (ix) the risk that our submissions to government payors may contain inaccurate or unsupportable information, including regarding risk adjustment scores of participants, subjecting us to repayment obligations or penalties; (x) and our ability to comply with the continued listing requirements of Nasdaq.

Forward-looking statements are based only on information currently available to us and speaks only as of the date on which they are made. Except as required by law, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. We advise you not to place undue reliance on forward-looking statements and to review our risk factors and other disclosures included in the reports we file or furnish with the Securities and Exchange Commission, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Note Regarding Use of Non-GAAP Financial Measures... (truncated)help investors and analysts in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance.

The Company’s management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments and allocating resources, predominantly in the annual budget and forecasting process. For the purpose of evaluating Center-level Contribution Margin on a center-by-center basis, we do not allocate our sales and marketing expense or corporate, general and administrative expenses across our centers. We define Center-level Contribution Margin as total revenues less external provider costs and cost of care, excluding depreciation and amortization, which includes all medical and pharmacy costs.

We define Adjusted EBITDA as net income (loss) adjusted for interest expense, net, other investment income, depreciation and amortization, and provision (benefit) for income tax as well as addbacks for non-recurring expenses or exceptional items, including charges relating to management equity compensation, litigation costs and settlement, M&A diligence, transaction and integration, business optimization, impairments and loss on assets held for sale, and loss (gain) on sale of assets. Adjusted EBITDA margin is Adjusted EBITDA expressed as a percentage of our total revenue.

Schedule 1

## Financial statements

### Income Statement (Three Months Ended March 31, — Financial Results (in thousands))

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Total revenues | 251,943 | 218,142 |
| Loss Before Income Taxes | -29,773 | -11,061 |
| Net Loss | -29,940 | -11,133 |
| Net Loss margin | -11.9% | -5.1% |
| Net Loss Attributable to InnovAge Holding Corp. | -29,461 | -11,378 |
| Net Loss per share - basic and diluted | -0.22 | -0.08 |
| Center-level Contribution Margin(1) | 61,020 | 40,747 |
| Adjusted EBITDA(1) | 30,495 | 10,792 |
| Adjusted EBITDA margin(1) | 12.1% | 4.9% |

### Income Statement

| | Revised Guidance – Low – dollars in millions | Revised Guidance – High – dollars in millions |
|---|---:|---:|
| Census | 7,900 | 8,100 |
| Total Member Months(1) | 92,900 | 95,700 |
| Total revenues | 950 | 975 |
| Adjusted EBITDA(2) | 85 | 90 |

### Income Statement (Three Months Ended March 31, — (IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA) (UNAUDITED))

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Revenues | Capitation revenue | 251,502 | 217,819 |
| Revenues | Other service revenue | 441 | 323 |
| Revenues | Total revenues | 251,943 | 218,142 |
| Expenses | External provider costs | 113,247 | 107,896 |
| Expenses | Cost of care, excluding depreciation and amortization | 77,676 | 69,499 |
| Expenses | Sales and marketing | 8,744 | 6,922 |
| Expenses | Corporate, general and administrative | 76,531 | 38,597 |
| Expenses | Depreciation and amortization | 4,824 | 5,386 |
| Expenses | Total expenses | 281,022 | 228,300 |
| Expenses | Operating Loss | -29,079 | -10,158 |
| Other Income (Expense) | Interest expense, net | -988 | -1,160 |
| Other Income (Expense) | Other income, net | 294 | 257 |
| Other Income (Expense) | Total other expense | -694 | -903 |
| Other Income (Expense) | Loss Before Income Taxes | -29,773 | -11,061 |
| Other Income (Expense) | Provision for Income Taxes | 167 | 72 |
| Other Income (Expense) | Net Loss | -29,940 | -11,133 |
| Other Income (Expense) | Less: net income (loss) attributable to noncontrolling interests | -479 | 245 |
| Other Income (Expense) | Net Loss Attributable to InnovAge Holding Corp. | -29,461 | -11,378 |
| Other Income (Expense) | Weighted-average number of common shares outstanding - basic | 135,704,645 | 135,200,314 |
| Other Income (Expense) | Weighted-average number of common shares outstanding - diluted | 135,704,645 | 135,200,314 |
| Other Income (Expense) | Net loss per share - basic | -0.22 | -0.08 |
| Other Income (Expense) | Net loss per share - diluted | -0.22 | -0.08 |

### Income Statement (Three months ended March 31, — Adjusted EBITDA)

| | Three months ended March 31, – 2026 | Three months ended March 31, – 2025 |
|---|---:|---:|
| Net loss | -29,940 | -11,133 |
| Interest expense, net | 988 | 1,160 |
| Other investment income(a) | -294 | -503 |
| Depreciation and amortization | 4,824 | 5,386 |
| Provision for income tax | 167 | 72 |
| Stock-based compensation | 1,790 | 2,035 |
| Litigation costs and settlement(b) | 51,859 | 13,277 |
| M&A diligence, transaction and integration(c) |  | 202 |
| Business optimization(d) | 1,101 | 152 |
| Impairments and loss on assets held for sale(e) |  | 144 |
| Adjusted EBITDA | 30,495 | 10,792 |
| Net income (loss) margin | -11.9 | -5.1 |
| Adjusted EBITDA margin | 12.1 | 4.9 |

### Income Statement (Three months ended December 31,)

| | Three months ended December 31, – 2025 |
|---|---:|
| Net income | 11,805 |
| Interest expense, net | 1,246 |
| Other investment income(a) | -483 |
| Depreciation and amortization | 4,877 |
| Provision for income tax | 651 |
| Stock-based compensation | 1,216 |
| Litigation costs and settlement(b) | 1,279 |
| Business optimization(c) | 1,560 |
| Adjusted EBITDA | 22,151 |
| Net income margin | 4.9 |
| Adjusted EBITDA margin | 9.2 |

### Income Statement (Three Months Ended March 31, 2026 — Center-Level Contribution Margin (in thousands))

| | Three Months Ended March 31, 2026 – PACE | Three Months Ended March 31, 2026 – Totals | Three Months Ended March 31, 2025 – PACE | Three Months Ended March 31, 2025 – All other(a) | Three Months Ended March 31, 2025 – Totals |
|---|---:|---:|---:|---:|---:|
| Capitation revenue | 251,502 | 251,502 | 217,819 |  | 217,819 |
| Other service revenue | 441 | 441 | 79 | 244 | 323 |
| Total revenues | 251,943 | 251,943 | 217,898 | 244 | 218,142 |
| External provider costs | 113,247 | 113,247 | 107,896 |  | 107,896 |
| Cost of care, excluding depreciation and amortization | 77,676 | 77,676 | 69,372 | 127 | 69,499 |
| Center-Level Contribution Margin | 61,020 | 61,020 | 40,630 | 117 | 40,747 |
| Sales and marketing |  | 8,744 |  |  | 6,922 |
| Corporate, general and administrative |  | 76,531 |  |  | 38,597 |
| Depreciation and amortization |  | 4,824 |  |  | 5,386 |
| Operating loss |  | -29,079 |  |  | -10,158 |
| Other expense |  | -694 |  |  | -903 |
| Loss Before Income Taxes |  | -29,773 |  |  | -11,061 |
| Loss Before Income Taxes as a percent of revenue |  | -11.8 |  |  | -5.1 |
| Center- Level Contribution Margin as a % of revenue |  | 24.2 |  |  | 18.7 |

### Income Statement (December 31, 2025 — Center-Level Contribution Margin (in thousands))

| | December 31, 2025 – PACE | December 31, 2025 – All other(1) | December 31, 2025 – Totals |
|---|---:|---:|---:|
| Capitation revenue | 239,620 |  | 239,620 |
| Other service revenue | 88 |  | 88 |
| Total revenues | 239,708 |  | 239,708 |
| External provider costs | 111,999 |  | 111,999 |
| Cost of care, excluding depreciation and amortization | 74,902 | -18 | 74,884 |
| Center-Level Contribution Margin | 52,807 | 18 | 52,825 |
| Sales and marketing |  |  | 8,078 |
| Corporate, general and administrative |  |  | 26,608 |
| Depreciation and amortization |  |  | 4,877 |
| Operating income (loss) |  |  | 13,262 |
| Other expense |  |  | -806 |
| Income Before Income Taxes |  |  | 12,456 |
| Income Before Income Taxes as a % of revenue |  |  | 5.2 |
| Center- Level Contribution Margin as a % of revenue |  |  | 22 |

### Balance Sheet ((IN THOUSANDS, EXCEPT NUMBER OF SHARES) (UNAUDITED))

| | March 31, 2026 | June 30, 2025 |
|---|---:|---:|
| Current Assets | Cash and cash equivalents | 95,536 | 64,129 |
| Current Assets | Short-term investments | 43,052 | 41,775 |
| Current Assets | Restricted cash | 10 | 11 |
| Current Assets | Accounts receivable | 28,584 | 36,373 |

### Cash Flow (Nine Months Ended March 31, — (IN THOUSANDS) (UNAUDITED) (in thousands))

| | Nine Months Ended March 31, – 2026 | Nine Months Ended March 31, – 2025 |
|---|---:|---:|
| Operating Activities | Net loss | -10,466 | -30,334 |
| Adjustments to reconcile net loss to net cash provided by operating activities | (Gain) loss on disposal of assets | -478 | 260 |
| Adjustments to reconcile net loss to net cash provided by operating activities | Provision for uncollectible accounts |  | 524 |
| Adjustments to reconcile net loss to net cash provided by operating activities | Depreciation and amortization | 14,786 | 16,116 |
| Adjustments to reconcile net loss to net cash provided by operating activities | Operating lease rentals | 4,603 | 4,738 |
| Adjustments to reconcile net loss to net cash provided by operating activities | Impairments and loss on assets held for sale | 104 | 8,495 |
| Adjustments to reconcile net loss to net cash provided by operating activities | Amortization of deferred financing costs | 532 | 322 |
| Adjustments to reconcile net loss to net cash provided by operating activities | Stock-based compensation | 5,314 | 6,069 |
| Adjustments to reconcile net loss to net cash provided by operating activities | Deferred income taxes | 521 | 509 |
| Adjustments to reconcile net loss to net cash provided by operating activities | Other, net | 2,039 | 1,173 |
| Changes in operating assets and liabilities | Accounts receivable | 7,789 | 3,183 |
| Changes in operating assets and liabilities | Prepaid expenses and other current assets | -7,566 | -6,275 |
| Changes in operating assets and liabilities | Income tax receivable | -77 |  |
| Changes in operating assets and liabilities | Deposits and other | -2,053 | -4,471 |
| Changes in operating assets and liabilities | Accounts payable and accrued expenses | 28,464 | 20,062 |
| Changes in operating assets and liabilities | Reported and estimated claims | 2,395 | 6,278 |
| Changes in operating assets and liabilities | Due to Medicaid and Medicare | 1,937 | 2,125 |
| Changes in operating assets and liabilities | Operating lease liabilities | -4,694 | -4,909 |
| Changes in operating assets and liabilities | Deferred revenue | 275 |  |
| Changes in operating assets and liabilities | Net cash provided by operating activities | 43,425 | 23,865 |
| Investing Activities | Purchases of property and equipment | -10,043 | -6,442 |
| Investing Activities | Purchases of short-term investments | -1,193 | -1,610 |
| Investing Activities | Proceeds from sale of assets held for sale | 3,716 |  |
| Investing Activities | Proceeds from sale of short-term investments |  | 6,300 |
| Investing Activities | Acquisition of business |  | -4,774 |
| Investing Activities | Net cash used in investing activities | -7,520 | -6,526 |
| Financing Activities | Payments for finance lease obligations | -4,002 | -3,147 |
| Financing Activities | Principal payments on long-term debt | -61,280 | -2,848 |
| Financing Activities | Proceeds from the issuance of long-term debt | 60,082 |  |
| Financing Activities | Payments on financing costs | -1,989 |  |
| Financing Activities | Repurchase of equity securities |  | -7,024 |
| Financing Activities | Contribution from joint venture partner | 3,200 |  |
| Financing Activities | Taxes paid related to net settlements of stock-based compensation awards | -428 | -814 |
| Financing Activities | Net cash used in financing activities | -4,417 | -13,833 |
